NovAccess Global Inc. is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States with plans to expand globally. We specialize in cutting-edge research related to utilizing a patient’s own immune system to attack the cancer. We are filing an Investigational New Drug Application (IND) and working closely with the Food and Drug Administration (FDA) to obtain approval for human clinical trials to determine the safety and efficacy of our drug product for brain cancer patients. Once we have successfully completed the clinical trials and proven that the new therapy is safe and efficacious, we plan to commercialize the product. We also have expertise in successfully executing clinical trials, bringing products to market and increasing the market size of products through our advisory board. Our scientists are well versed in immunology, stem cell biology, neuroscience, molecular biology, imaging, small molecules development, gene therapy and other technical assays needed for protein and genetic analysis of cancer cells.
Company profile
Ticker
XSNX, XSNXD
Exchange
Website
CEO
Thomas M. Djokovich
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SUN RIVER MINING INC, XSUNX INC
SEC CIK
Corporate docs
IRS number
841384159
XSNX stock data
Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
24 Apr 24
8-K
Entry into a Material Definitive Agreement
28 Feb 24
10-Q
2024 Q1
Quarterly report
27 Feb 24
NT 10-Q
Notice of late quarterly filing
15 Feb 24
10-K
2023 FY
Annual report
9 Feb 24
8-K
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
6 Feb 24
8-K
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
22 Jan 24
8-K
Entry into a Material Definitive Agreement
5 Jan 24
8-K
NovAccess Global Announces $10.7 Million Financing
2 Jan 24
NT 10-K
Notice of late annual filing
2 Jan 24
Latest ownership filings
SC 13G
AJB Capital Investments LLC
18 Jan 24
4
NEIL J LAIRD
15 Mar 23
4
JOHN CASSARINI
15 Mar 23
4
Jason Michael Anderson
15 Mar 23
SC 13G
AJB Capital Investments LLC
23 Feb 23
SC 13G
AJB Capital Investments LLC
17 May 22
3
Jason Michael Anderson
30 Mar 22
3
JOHN CASSARINI
24 Mar 22
SC 13D/A
Martin Daniel G.
14 Mar 22
SC 13D/A
Morris-Irvin Dwain
14 Mar 22
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 22 | Sep 21 | Sep 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 61.46 k | 61.46 k | 61.46 k | 61.46 k | 61.46 k | 61.46 k |
Cash burn (monthly) | (no burn) | 2.37 k | 161.55 k | 195.85 k | 37.76 k | 55.61 k |
Cash used (since last report) | n/a | 23.47 k | 1.60 mm | 1.94 mm | 373.46 k | 550.02 k |
Cash remaining | n/a | 38.00 k | -1.54 mm | -1.88 mm | -311.99 k | -488.56 k |
Runway (months of cash) | n/a | 16.0 | -9.5 | -9.6 | -8.3 | -8.8 |
Institutional ownership, Q4 2022
27.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 7.50 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Dwain Morris-Irvin | 6.00 mm | $0.00 |
Martin Daniel G. | 1.50 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Mar 23 | Jason Michael Anderson | Stock Option Common Stock | Grant | Acquire A | No | No | 0.175 | 857,143 | 150.00 k | 857,143 |
13 Mar 23 | John Cassarini | Stock Option Common Stock | Grant | Acquire A | No | No | 0.175 | 857,143 | 150.00 k | 857,143 |
13 Mar 23 | Neil J Laird | Stock Option Common Stock | Grant | Acquire A | No | No | 0.175 | 428,571 | 75.00 k | 428,571 |